Osteoporosis in men is finally receiving some attention; it has been realized 
that men are more likely to die after hip fracture. Methods for screening men 
for osteoporosis include dual energy x-ray absorptiometry and use of fracture 
risk calculators such as FRAX (World Health Organization) and the Garvan 
nomogram. Evaluation of men will often identify secondary causes of osteoporosis 
as well as multiple risk factors. Alendronate, risedronate, zoledronic acid, and 
teriparatide are US Food and Drug Administration (FDA)--approved therapy for 
men. Men on androgen deprivation therapy (ADT) are at high risk for bone loss 
and fracture, and all the bisphosphonates have been shown to increase bone 
density. The new antiresorptive drug, denosumab, although FDA-approved only for 
postmenopausal women, has been shown in a study of men on ADT to increase bone 
density in spine, hip, and forearm and decrease vertebral fractures on x-ray. 
Thus, there is great progress in osteoporosis in men, and recognition of its 
importance is increasing.